Final analyses of OPTiM: a randomized phase III trial of talimogene laherparepvec versus granulocyte-macrophage colony-stimulating factor in unresectable stage III–IV melanoma

Final analyses of OPTiM: a randomized phase III trial of talimogene laherparepvec versus granulocyte-macrophage colony-stimulating factor in unresectable stage III–IV melanoma

Abstract Background Talimogene laherparepvec is an oncolytic immunotherapy approved in the US, Europe, Australia and Switzerland. We report the final planned analysis of OPTiM, a randomized open-label phase III trial in patients with unresectable stage IIIB–IVM1c melanoma. Methods Patients were rand...

Full description

Bibliographic Details
Main Authors: Robert H. I. Andtbacka, Frances Collichio, Kevin J. Harrington, Mark R. Middleton, Gerald Downey, Katarina Ӧhrling, Howard L. Kaufman
Format: Article
Language:English
Published: BMJ Publishing Group 2019-06-01
Series:Journal for ImmunoTherapy of Cancer
Subjects:
Efficacy
Final analysis
Melanoma
Overall survival
Talimogene laherparepvec
Online Access:http://link.springer.com/article/10.1186/s40425-019-0623-z

Internet

http://link.springer.com/article/10.1186/s40425-019-0623-z

Similar Items